PACAP (6–38) is a PACAP receptor antagonist for breast cancer cells
- 1 July 1999
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 56 (2) , 175-184
- https://doi.org/10.1023/a:1006262611290
Abstract
The effects of pituitary adenylate cyclase activating polypeptide (PACAP) analogs were investigated using breast cancer cells. 125I–PACAP–27 bound with high affinity (Kd=5 nM) to T47D cells...Keywords
This publication has 30 references indexed in Scilit:
- PACAP stimulates c-fos mRNAs in small cell lung cancer cellsLife Sciences, 1996
- Multiple receptors for PACAP and VIPTrends in Pharmacological Sciences, 1994
- Type I receptors for PACAP (a neuropeptide even more important than VIP?)Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1993
- Differential signal transduction by five splice variants of the PACAP receptorNature, 1993
- Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor.Proceedings of the National Academy of Sciences, 1993
- Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cellsPeptides, 1993
- Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptideNeuron, 1992
- Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38)Biochemical and Biophysical Research Communications, 1990
- Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cellsBiochemical and Biophysical Research Communications, 1989
- Polypeptide with Broad Biological Activity: Isolation from Small IntestineScience, 1970